Legend Biotech is preparing a leadership transition, with plans to appoint Ingrid Zhang as its new chief executive officer. Zhang, currently an executive at Novartis, is expected to step into the role as the company continues its focus on cancer-treatment development. The move signals a strategic shift for the biotech firm as it navigates a cooling market environment where defensive health plays have outperformed many growth-oriented alternatives.
Legend Biotech Taps Novartis Executive for CEO Role
Investors are shifting capital toward health care as the sector proves more resilient than the broader market against ongoing inflation and interest-rate volatility. While major indices faced sharper declines during the latest trading session, health-related equities maintained relative stability, drawing interest from traders seeking defensive positions amid broader economic uncertainty.
Comments (0)
No comments yet. Be the first!